Resistance to Targeted ABC Transporters in Cancer

  • Thomas Efferth

Part of the Resistance to Targeted Anti-Cancer Therapeutics book series (RTACT, volume 4)

Table of contents

  1. Front Matter
    Pages i-x
  2. E. A. Roundhill, J. I. Fletcher, M. Haber, M. D. Norris
    Pages 27-52
  3. Karthika Natarajan, Maria R. Baer, Douglas D. Ross
    Pages 53-88
  4. Toshihisa Ishikawa, Yutaka Inoue, Yoji Ikegami, Takahiro Fujishiro, Tomohiro Osaki, Yoshinaga Kajimoto et al.
    Pages 89-104
  5. Atish Patel, De-Shen Wang, Hong-May Sim, Suresh V. Ambudkar, Zhe-Sheng Chen
    Pages 183-208
  6. Csilla Hegedüs, Tamás Hegedüs, Balázs Sarkadi
    Pages 209-244
  7. Sohail Akhter, Saima Amin, Javed Ahmad, Saba Khan, Mohd Anwar, Mohammad Zaki Ahmad et al.
    Pages 245-272
  8. Kazuhiro Satake, Yu Toyoda, Hiroshi Nakagawa
    Pages 273-297
  9. Atish Patel, De-Shen Wang, Hong-May Sim, Suresh V. Ambudkar, Zhe-Sheng Chen
    Pages E1-E1
  10. Back Matter
    Pages 299-300

About this book


This volume covers the most current topics relevant to ABC transporters and resistance to novel and established anticancer drugs, prognosis of patients to compounds to modulate multidrug resistance, compounds used in photodynamic therapy, tyrosine kinase inhibitors and others. Furthermore, the potential of radiopharmaceuticals for diagnosis of multidrug-resistant tumors is also discussed.

The development of resistance is a major obstacle in cancer chemotherapy since decades. Drug resistance may develop during repeated treatment cycles after initially successful therapy (acquired or secondary resistance). Alternatively, tumors may be resistant from the beginning (inherent or primary resistance). The failure of chemotherapy is a major reason for the fatal outcome of tumor diseases in many patients. Even worse, tumors frequently develop not only resistance to single drugs, but also to many others at the same time. This phenomenon was termed multidrug resistance and decreases the success rates of therapy regimens with combinations of structurally and functionally different drugs. The uncommonly broad spectrum of anticancer agents that are transported by ABC transporters makes these proteins exquisite targets to search for compounds that inhibit their transport function. A huge amount of compounds from many pharmacologically established drug were observed to inhibit ABC transporters and to reverse multidrug resistance—all of these topics and more is explored in this volume.


P-glycoprotein anticancer drugs multidrug resistance nanotechnology

Editors and affiliations

  • Thomas Efferth
    • 1
  1. 1.Department of Pharmaceutical BiologyJohannes Gutenberg UniversityMainzGermany

Bibliographic information

  • DOI
  • Copyright Information Springer International Publishing Switzerland 2015
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-3-319-09800-5
  • Online ISBN 978-3-319-09801-2
  • Series Print ISSN 2196-5501
  • Series Online ISSN 2196-551X
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods